Esophageal Cancer
AF risk elevated among patients with cancer; degree depends on cancer type
Patients with cancer have elevated risk for atrial fibrillation development, although the degree varies by cancer type, researchers reported in JACC: CardioOncology.
Intensive surveillance following esophageal cancer may improve outcomes
Preoperative pembrolizumab may enhance major pathologic response in esophageal cancer
Adding pembrolizumab to preoperative chemoradiotherapy increased major pathologic response rate compared with historical data among patients with esophageal adenocarcinoma, according to a study presented at the virtual ASCO Annual Meeting.
Two nivolumab regimens outperform chemotherapy alone in advanced esophageal cancer
The addition of nivolumab to chemotherapy or ipilimumab significantly improved OS compared with chemotherapy alone among patients with previously untreated advanced esophageal squamous cell carcinoma, according to phase 3 study findings.
FDA approves Opdivo for esophageal, gastroesophageal junction cancers
The FDA approved nivolumab as adjuvant treatment for certain patients with completely resected esophageal or gastroesophageal junction cancers, according to the agent’s manufacturer.
Tislelizumab extends OS in advanced esophageal cancer
Tislelizumab extended OS compared with chemotherapy for patients with previously treated advanced esophageal squamous cell carcinoma, according to topline data released by the agent’s manufacturer.
FDA grants priority review to Opdivo for gastric, esophageal cancer indications
The FDA granted priority review to nivolumab for two gastrointestinal cancer indications, according to the agent’s manufacturer.
Certain oral bacteria linked to higher risk for esophageal cancer
Oral bacteria appeared to be more abundant in patients with esophageal cancer compared with otherwise healthy controls, according to results of a study published in Cancer.
FDA grants priority review to Keytruda-chemotherapy regimen for esophageal cancer
Pembrolizumab plus fluoropyrimidine-based chemotherapy received FDA priority review for the first-line treatment of locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer, according to a press release.